Improving clinical care of patients in Nipah outbreaks: moving beyond ‘compassionate use’

The Lancet Regional Health - Southeast Asia, Journal Year: 2025, Volume and Issue: 33, P. 100527 - 100527

Published: Jan. 5, 2025

The 2024 Nipah outbreak in Kerala, India-its fifth six years-and the recurring annual outbreaks Bangladesh underscore persistent threat posed by virus (NiV) region. With a high mortality rate, human-to-human transmission potential, and widespread presence of Pteropus bats, natural reservoir, NiV remains significant epidemic threat. Despite being WHO priority pathogen, there has been no systematic effort to improve patient care for NiVD, leading consistently poor outcomes. Current relies on supportive measures 'compassionate use' unapproved drugs like ribavirin remdesivir. Drugs used 'off-label' during can become 'standard care' without robust evidence their safety or efficacy, complicating testing new therapies perpetuating uncertainty about true effectiveness. To NiVD care, we propose four key strategies: 1) Enhance early case detection, 2) optimize outcomes create standard future trials, 3) adopt syndromic approach centered encephalitis, 4) explore innovative trial designs tailored low numbers as an alternative use'. By integrating these strategies, healthcare systems NiV-endemic regions will be better equipped manage both current outbreaks.

Language: Английский

Advancements in nipah virus vaccine development:Current trends and challenges

LabMed discovery., Journal Year: 2025, Volume and Issue: unknown, P. 100044 - 100044

Published: March 1, 2025